---
schema_version: "secwatch.filing_event.v1"
accession: "0001809519-26-000151"
form_type: "8-K"
ticker: "GDRX"
cik: "0001809519"
company_name: "GoodRx Holdings, Inc."
filed_at: "2026-08-05T20:07:39+00:00"
generated_at: "2026-08-05T20:10:23.230823+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GoodRx Q2 revenue $200.4M, Pharma Direct +76% YoY; raises FY2026 guidance

## Summary
- Revenue $200.4M; net income $8.5M (4.3% margin); adjusted EBITDA $63.7M (31.8% margin).
- Pharma Direct revenue up 76% YoY; Subscription revenue up 39% YoY.
- Company raises full-year 2026 revenue and adjusted EBITDA expectations.
- Adjusted net income $26.8M (13.4% margin); net cash from operations $80.8M.

## SEC filing metadata
- accession: 0001809519-26-000151
- form_type: 8-K
- ticker: GDRX
- cik: 0001809519
- company_name: GoodRx Holdings, Inc.
- filed_at: 2026-08-05T20:07:39+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1809519/000180951926000151/0001809519-26-000151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1809519/000180951926000151/gdrx-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001809519-26-000151
- JSON: https://secwatch.observer/filing/0001809519-26-000151.json
- Plain text: https://secwatch.observer/filing/0001809519-26-000151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.